NCT01331083View on ClinicalTrials.gov

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 9, 2011

Primary Completion Date

January 13, 2015

Study Completion Date

November 27, 2015

Conditions
Prostate Cancer
Interventions
DRUG

PX-866

PX-866: 8mg orally taken daily

Trial Locations (10)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors
All Listed Sponsors
collaborator

Oncothyreon Canada Inc.

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK

NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter